Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Algenpantucel-L - Lumos Pharma

Next Previous
Drug Profile

Algenpantucel-L - Lumos Pharma

Alternative Names: HAPa; HyperAcute Pancreas; HyperAcute-Pancreas-Immunotherapy; Pancreatic cancer vaccine - Lumos Pharma

Latest Information Update: 22 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NewLink Genetics Corporation
  • Developer Lumos Pharma
  • Class Cancer vaccines; Cell therapies; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pancreatic cancer

Most Recent Events

  • 08 Dec 2020 US FDA withdraws IND applicaion for a long term follow-up phase III trial for Pancreatic cancer in USA (Intradermal) (NCT03165188)
  • 08 Dec 2020 NewLink Genetics and Lumos Pharma terminates a long term follow-up phase III trial for Pancreatic cancer in USA (Intradermal) (NCT03165188)
  • 26 Feb 2019 NewLink Genetics Corporation terminates the phase III PILLAR trial in Pancreatic cancer (Combination therapy, Inoperable/Unresectable) in USA (Intradermal) (NCT01836432)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top